Welcome to our dedicated page for Quoin Pharmaceuticals, Ltd. American Depositary Shares news (Ticker: $QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals, Ltd. American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quoin Pharmaceuticals, Ltd. American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quoin Pharmaceuticals, Ltd. American Depositary Shares's position in the market.
Quoin Pharmaceuticals, a specialty pharmaceutical company, announced positive clinical developments in Netherton Syndrome, including FDA clearance for teen recruitment and protocol amendments for ongoing studies. The company extended its cash runway into late 2025 and expanded its patent portfolio. Financially, Quoin had $14.7 million in cash, with a net loss of $2.3 million for the first quarter of 2024.
Quoin Pharmaceuticals (QNRX) will reveal its first quarter 2024 financial results on May 9th, 2024. The announcement will cover operational progress and financial highlights.